Pharming Group Valuation
| PHAR Stock | USD 7.76 0.08 1.04% |
Based on Macroaxis valuation methodology, the company cannot be evaluated at this time. Pharming Group NV recent Real Value cannot be determined due to lack of data. The prevailing price of Pharming Group NV is $7.76. Our model determines the value of Pharming Group NV from analyzing the company fundamentals such as Operating Margin of 0.05 %, shares outstanding of 67.84 M, and Return On Equity of -0.0818 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Pharming Group's valuation include:
Price Book 2.3314 | Enterprise Value 457.1 M | Enterprise Value Ebitda 60.5011 | Price Sales 1.8422 | Forward PE 169.4915 |
Undervalued
Today
Please note that Pharming Group's price fluctuation is out of control at this time. Calculation of the real value of Pharming Group NV is based on 3 months time horizon. Increasing Pharming Group's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Pharming stock is determined by what a typical buyer is willing to pay for full or partial control of Pharming Group NV. Since Pharming Group is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Pharming Stock. However, Pharming Group's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 7.76 | Real 0.0 | Target 33.5 | Hype 0.0 | Naive 7.68 |
The intrinsic value of Pharming Group's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Pharming Group's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Pharming Group NV helps investors to forecast how Pharming stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Pharming Group more accurately as focusing exclusively on Pharming Group's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Pharming Group's intrinsic value based on its ongoing forecasts of Pharming Group's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Pharming Group's closest peers.
Pharming Group Cash |
|
Pharming Valuation Trend
Pharming Group's real value is important for investors to make better decisions and a more accurate overall view of Pharming Group's financial worth over time. Using both Pharming Group's enterprise value as well as its market capitalization is the best way to gauge the value of the company and is usually enough for investors to make market timing conclusions.
Pharming Group Total Value Analysis
Pharming Group NV is at this time forecasted to have valuation of 457.15 M with market capitalization of 526.4 M, debt of 171.54 M, and cash on hands of 189.96 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Pharming Group fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
457.15 M | 526.4 M | 171.54 M | 189.96 M |
Pharming Group Investor Information
The book value of the company was at this time reported as 0.44. The company recorded a loss per share of 0.27. Pharming Group NV had not issued any dividends in recent years. Based on the analysis of Pharming Group's profitability, liquidity, and operating efficiency, Pharming Group NV is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Pharming Group Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Pharming Group has an asset utilization ratio of 53.0 percent. This connotes that the Company is making $0.53 for each dollar of assets. An increasing asset utilization means that Pharming Group NV is more efficient with each dollar of assets it utilizes for everyday operations.Pharming Group Ownership Allocation
Pharming Group owns a total of 67.84 Million outstanding shares. Roughly 99.9 pct. of Pharming Group outstanding shares are held by general public with 0.1 (%) by third-party entities. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.Pharming Group Profitability Analysis
The company reported the previous year's revenue of 245.32 M. Net Loss for the year was (9.55 M) with profit before overhead, payroll, taxes, and interest of 188.06 M.About Pharming Group Valuation
The stock valuation mechanism determines Pharming Group's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Pharming Group NV based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pharming Group. We calculate exposure to Pharming Group's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Pharming Group's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 220.1 M | 231.1 M | |
| Pretax Profit Margin | (0.04) | (0.05) | |
| Operating Profit Margin | (0.02) | (0.02) | |
| Net Loss | (0.04) | (0.04) | |
| Gross Profit Margin | 0.90 | 0.94 |
Pharming Group Growth Indicators
Investing in growth stocks can be very risky. If the company such as Pharming Group does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 67.5 M | |
| Quarterly Earnings Growth Y O Y | -0.615 | |
| Forward Price Earnings | 169.4915 |
Pharming Group Current Valuation Indicators
Pharming Group's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Pharming Group's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Pharming Group, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Pharming Group's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Pharming Group's worth.Additional Tools for Pharming Stock Analysis
When running Pharming Group's price analysis, check to measure Pharming Group's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharming Group is operating at the current time. Most of Pharming Group's value examination focuses on studying past and present price action to predict the probability of Pharming Group's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharming Group's price. Additionally, you may evaluate how the addition of Pharming Group to your portfolios can decrease your overall portfolio volatility.